Inactivated SARS-CoV-2 vaccine shows safety and antibody response in early trials
In short: Researchers conducting a phase 1/2 clinical trial found that an inactivated SARS-CoV-2 vaccine candidate, CoronaVac, was generally well-tolerated by healthy adults. The study observed that participants who received the vaccine showed significant increases in neutralizing antibody seroconversion compared to those who received a placebo.
The study was a randomized, double-blind, placebo-controlled trial involving 743 participants across two phases. Researchers measured safety through adverse reaction rates and immunogenicity via antibody seroconversion.
While the results suggest the vaccine is safe and triggers an immune response, the study was limited to a relatively small number of participants in a specific geographic area.
Why it matters: The vaccine showed promise in early-phase trials for safety and immune response.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Zhang et al. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet. Infectious diseases.
To cite this card, link to https://intellectplus.co.uk/app/health-research-inactivated-sars-cov-2-vaccine-shows-safety-and-antibody-res.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Immunology · More in Health · Latest · A–Z · All topics
